市场调查报告书

癌症治疗的全球市场

Cancer Therapies

出版商 Global Industry Analysts, Inc. 商品编码 912478
出版日期 内容资讯 英文 915 Pages
商品交期: 最快1-2个工作天内
价格
癌症治疗的全球市场 Cancer Therapies
出版日期: 2020年09月01日内容资讯: 英文 915 Pages
简介

本报告提供全球癌症治疗市场概要,提供趋势·发展的影响因素分析,竞争企业与市场占有率,世界及各地区·各主要国家的市场规模的变化与预测,主要企业简介等资讯。

第1章 调查手法

第2章 摘要整理

  • 市场概要
    • 全球市场的企业占有率
    • 全球癌症治疗市场上企业占有率方案
  • 主要企业
  • 市场趋势与发展因素
  • 全球市场预测

第3章 市场分析

  • 各地区市场分析
    • 美国
    • 加拿大
    • 日本
    • 中国
    • 欧洲
    • 法国
    • 德国
    • 义大利
    • 英国
    • 西班牙
    • 俄罗斯
    • 其他欧洲
    • 亚太地区
    • 澳洲
    • 印度
    • 韩国
    • 其他亚太地区
    • 南美
    • 阿根廷
    • 巴西
    • 墨西哥
    • 其他南美国家
    • 中东
    • 伊朗
    • 以色列
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 其他中东
    • 非洲

第4章 竞争企业

  • AMGEN
  • ASTRAZENECA PLC
  • BAYER AG
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER

第5章 调查资料

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: MCP-1551

The global market for Cancer Therapies is projected to reach US$220.5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease. Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities.

Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancer`s diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancer`s mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing`. Aberrations in alternative splicing are linked to cancer`s progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancer`s biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide.

Competitors identified in this market include, among others,

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • Cancer Therapies: An Outlook
    • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
    • By Cancer Type
    • USA Leads the Cancer Therapies Market
    • Biotherapies to Drive Growth
    • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
    • Total Number of New Cancer Cases by Type:
    • Total Number of Cancer Deaths by Type:
    • Cancer Incidence by Region:
    • Cancer Mortality by Region:
    • Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region:
    • Cancer Research Spending Continues to Witness Growth
    • Number of FDA-Approved Cancer Drugs: 2010
    • Select Cancer Drug Approvals in
    • Select Cancer Drug Approvals in
    • Cancer Drug Pipeline to Change the Pharma Landscape
    • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010
    • Global Competitor Market Shares
    • Cancer Therapies Competitor Market Share Scenario Worldwide (in %):
    • Select Leading Cancer Drugs Worldwide by Sales:
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Industry Focuses on New Approaches to Treat Cancer
    • Recent Advancements in Cancer Drug Discovery
    • A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
    • Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
    • New Linker Technology for Enhancing Stability of ADCs
    • Personalized Medicine Gains Importance
    • Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
    • North American Companion Diagnostics Market (2019)
    • European Companion Diagnostics Market by Disease Area (2019)
    • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
    • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
    • Combination Therapy: A Double Whammy Success
    • Patent Expiries of Branded Drugs to Trigger Generic Competition
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
    • Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
    • Development of Novel Drug Candidates and Potential Therapies
    • Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
    • Rise in Patient Assistance Programs (PAPs)
    • Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
    • Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
    • Growth Drivers and Restraints
    • Demographics & Lifestyles Raise the Risk of Cancer
    • Percentage Breakdown of New Cases for All Cancers by Gender (2019)
    • Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
    • Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
    • Unmet Needs Leave Scope for Further Research and Development
    • Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
    • Increasing Investments by National Health Authorities
    • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
    • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
    • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
    • Innovations, Improvements, and Approvals Propel Growth
    • Select Cancer Drug Approvals (2018 & 2019)
    • Emerging Challenges in Cancer Drug Development
    • Drug Failures Deter Prospects of New Therapies
    • High Prices of Targeted Therapies Act as a Speed Breaker
    • Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of
    • Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
    • Limited Tumor Specificity and Toxicity
    • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
    • Reduced Smoking
    • Global Cigarette Consumption Per Capita by Select Countries for 1970 and
    • Reimbursement Coverage Remains a Major Challenge
    • Increase in Multidrug Resistance
    • Stringent Regulations Delay Market Approval
    • Challenges Encountered in Clinical Trials
    • Overview of Cancer Therapy Segments
    • Immunotherapy: A Promising Segment
    • Global Cancer Immunotherapy Market by Therapy Type (in %) for
    • Monoclonal Antibodies for Cancer Treatment
    • Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
    • Vaccines: A Promising Future Area of Cancer Therapeutics
    • Approved Therapeutic Cancer Vaccines Worldwide
    • CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients' Immune Cells for Cancer Treatment
    • UK Researchers New Approach Holds Potential to Boost Immunotherapies
    • Targeted Therapy: An Overview
    • Types of Targeted Therapy
    • Chemotherapy: An Overview
    • Types of Chemotherapy
    • Risks Associated with Chemotherapy
    • Hormone Therapy
    • Drug Classes in Hormone Therapy
    • CANCER TYPES, APPROVED AND PIPELINE DRUGS
    • Prostate Cancer
    • Global Sales of Leading Prostate Cancer Drugs in US$ Million:
    • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
    • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
    • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
    • Prostate Cancer Phase IV Completed Clinical Trials with Results
    • Lung Cancer
    • Age-Standardized Lung Cancer Rates for Select Countries
    • Age-Standardized Lung Cancer Rates in Men for Select Countries
    • Age-Standardized Lung Cancer Rates in Women for Select Countries
    • Select FDA-Approved Non-Small Cell Lung Cancer Drugs
    • Select Phase IV Completed Clinical Trials with Results: As of Dec,
    • Select Phase III Completed Clinical Trials with Results: As of December 30,
    • Breast Cancer
    • Select FDA Approved Breast Cancer Drugs
    • Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30,
    • Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30,
    • Renal Cancer
    • Select FDA-Approved Renal Cell Carcinoma Drugs
    • Cervical Cancer
    • Colorectal Cancer
    • Select FDA-Approved Colorectal Cancer Drugs
    • Skin Cancer
    • Pancreatic Cancer
    • Non-Hodgkin's Lymphoma
    • Leukemia
    • Standard Approved Mode of Therapy for AML by Age Group
    • Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30,
    • Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30,
    • Bladder Cancer
    • Endometrial Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 2: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 3: World 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2009, 2020 & 2025
    • TABLE 4: World Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 6: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 7: World Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 8: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 9: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 10: World Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 12: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 13: World Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 14: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 15: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 16: World Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 17: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 18: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 19: World Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 20: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 21: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 22: World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 23: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 24: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 25: World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 26: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 27: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 28: World Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 29: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 30: World 16-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 31: World Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 32: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 33: World 16-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 34: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 35: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 36: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025
    • TABLE 37: World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 38: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 39: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2009, 2020 & 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Overview
    • Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market
    • Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and
    • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
    • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010
    • Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
    • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
    • A Surging US Prostate Cancer Therapeutics Market
    • Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
    • Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
    • CMS Hikes Reimbursement Rate for CAR-T Therapy
    • Market Analytics
    • TABLE 40: USA Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 41: USA Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 42: USA 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 43: USA Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 44: USA Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 45: USA 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • CANADA
    • Number of New Cancer Cases in Canada:
    • Market Analytics
    • TABLE 46: Canada Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 47: Canada Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 48: Canada 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 49: Canada Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 50: Canada Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 51: Canada 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • JAPAN
    • TABLE 52: Japan Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 53: Japan Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 54: Japan 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 55: Japan Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 56: Japan Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 57: Japan 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • CHINA
    • Cancer Therapies Market: Overview
    • Number of New Cancer Cases Diagnosed (in Thousands) in China:
    • Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
    • Market Analytics
    • TABLE 58: China Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 59: China Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 60: China 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 61: China Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 62: China Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 63: China 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • EUROPE
    • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
    • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for
    • Number of New Cancer Cases Diagnosed (in Thousands) in the UK:
    • Market Analytics
    • TABLE 64: Europe Current & Future Analysis for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 65: Europe Historic Review for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 66: Europe 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2020 & 2025
    • TABLE 67: Europe Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 68: Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 69: Europe 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 70: Europe Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 71: Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 72: Europe 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • FRANCE
    • TABLE 73: France Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 74: France Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 75: France 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 76: France Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 77: France Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 78: France 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • GERMANY
    • TABLE 79: Germany Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 80: Germany Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 81: Germany 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 82: Germany Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 83: Germany Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 84: Germany 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • ITALY
    • TABLE 85: Italy Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 86: Italy Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 87: Italy 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 88: Italy Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 89: Italy Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 90: Italy 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • UNITED KINGDOM
    • TABLE 91: UK Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 92: UK Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 93: UK 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 94: UK Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 95: UK Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 96: UK 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • SPAIN
    • TABLE 97: Spain Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 98: Spain Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 99: Spain 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 100: Spain Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 101: Spain Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 102: Spain 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • RUSSIA
    • TABLE 103: Russia Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 104: Russia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 105: Russia 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 106: Russia Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 107: Russia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 108: Russia 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • REST OF EUROPE
    • TABLE 109: Rest of Europe Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 110: Rest of Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 111: Rest of Europe 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 112: Rest of Europe Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 113: Rest of Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 114: Rest of Europe 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • ASIA-PACIFIC
    • An Insight into Asia-Pacific Market for Cancer Therapies
    • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for
    • Market Analytics
    • TABLE 115: Asia-Pacific Current & Future Analysis for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 116: Asia-Pacific Historic Review for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 117: Asia-Pacific 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2009, 2020 & 2025
    • TABLE 118: Asia-Pacific Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 119: Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 120: Asia-Pacific 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 121: Asia-Pacific Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 122: Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 123: Asia-Pacific 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • AUSTRALIA
    • TABLE 124: Australia Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 125: Australia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 126: Australia 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 127: Australia Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 128: Australia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 129: Australia 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • INDIA
    • TABLE 130: India Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 131: India Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 132: India 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 133: India Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 134: India Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 135: India 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • SOUTH KOREA
    • TABLE 136: South Korea Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 137: South Korea Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 138: South Korea 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 139: South Korea Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 140: South Korea Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 141: South Korea 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • REST OF ASIA-PACIFIC
    • TABLE 142: Rest of Asia-Pacific Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 143: Rest of Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 144: Rest of Asia-Pacific 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 145: Rest of Asia-Pacific Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 146: Rest of Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 147: Rest of Asia-Pacific 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • LATIN AMERICA
    • TABLE 148: Latin America Current & Future Analysis for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 149: Latin America Historic Review for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 150: Latin America 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2009, 2020 & 2025
    • TABLE 151: Latin America Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 152: Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 153: Latin America 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 154: Latin America Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 155: Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 156: Latin America 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • ARGENTINA
    • TABLE 157: Argentina Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 158: Argentina Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 159: Argentina 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 160: Argentina Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 161: Argentina Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 162: Argentina 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • BRAZIL
    • TABLE 163: Brazil Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 164: Brazil Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 165: Brazil 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 166: Brazil Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 167: Brazil Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 168: Brazil 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • MEXICO
    • TABLE 169: Mexico Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 170: Mexico Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 171: Mexico 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 172: Mexico Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 173: Mexico Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 174: Mexico 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • REST OF LATIN AMERICA
    • TABLE 175: Rest of Latin America Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 176: Rest of Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 177: Rest of Latin America 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 178: Rest of Latin America Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 179: Rest of Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 180: Rest of Latin America 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • MIDDLE EAST
    • TABLE 181: Middle East Current & Future Analysis for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through
    • TABLE 182: Middle East Historic Review for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 183: Middle East 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2009, 2020 & 2025
    • TABLE 184: Middle East Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 185: Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 186: Middle East 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 187: Middle East Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 188: Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 189: Middle East 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • IRAN
    • TABLE 190: Iran Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 191: Iran Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 192: Iran 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 193: Iran Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 194: Iran Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 195: Iran 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • ISRAEL
    • TABLE 196: Israel Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 197: Israel Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 198: Israel 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 199: Israel Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 200: Israel Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 201: Israel 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • SAUDI ARABIA
    • TABLE 202: Saudi Arabia Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 203: Saudi Arabia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 204: Saudi Arabia 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 205: Saudi Arabia Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 206: Saudi Arabia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 207: Saudi Arabia 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • UNITED ARAB EMIRATES
    • TABLE 208: UAE Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 209: UAE Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 210: UAE 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 211: UAE Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 212: UAE Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 213: UAE 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • REST OF MIDDLE EAST
    • TABLE 214: Rest of Middle East Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 215: Rest of Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 216: Rest of Middle East 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 217: Rest of Middle East Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 218: Rest of Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 219: Rest of Middle East 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025
  • AFRICA
    • TABLE 220: Africa Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 221: Africa Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 222: Africa 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2009, 2020 & 2025
    • TABLE 223: Africa Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through
    • TABLE 224: Africa Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2009 through
    • TABLE 225: Africa 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2009, 2020 & 2025

IV. COMPETITION

  • Total Companies Profiled: 75